茚地那韦、司他夫定（d4T）和去羟肌苷（ddI）联合治疗感染人类免疫缺陷病毒儿童的一项试点研究。
A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus.
作者信息
Kline M W, Fletcher C V, Harris A T, Evans K D, Brundage R C, Remmel R P, Calles N R, Kirkpatrick S B, Simon C
机构信息
Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston 77030, USA.
出版信息
J Pediatr. 1998 Mar;132(3 Pt 1):543-6. doi: 10.1016/s0022-3476(98)70039-3.
Twelve children infected with the human immunodeficiency virus were treated orally with indinavir, stavudine, plus didanosine for 12 to 48 weeks. Therapy was limited in some cases by nonadherence, intolerance, toxicity, and virologic failure. Marked increases in CD4+ lymphocyte counts and decreases in plasma human immunodeficiency virus RNA concentrations suggest that the regimen has potent antiviral activity.
12名感染人类免疫缺陷病毒的儿童接受了茚地那韦、司他夫定加去羟肌苷的口服治疗，疗程为12至48周。在某些情况下，治疗受到不依从、不耐受、毒性和病毒学失败的限制。CD4 +淋巴细胞计数显著增加和血浆人类免疫缺陷病毒RNA浓度降低表明该方案具有强大的抗病毒活性。
Zotero 插件